IP Library Granted Patent US 6,949,554
Granted Patent B2
US 6,949,554 · App. 10/746,932 · Granted Sep 27, 2005

Calcium channel blockers comprising two benzhydril moieties

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,949,554
App. No.
10/746,932
Granted
Sep 27, 2005
Kind
B2
Abstract

Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Claims (25)

1. A method to treat a condition selected from the group consisting of pain, stroke, epilepsy, anxiety and depression in a subject, which method comprises administering to a subject in need of such treatment an amount of a compound of formula (1) effective to treat said condition wherein said compound of formula (1) is:

or a pharmaceutically acceptable salt thereof

wherein each R 1 -R 5 is independently optionally substituted alkyl (1-10C), alkenyl (2-10C), alkynyl (2-10C), aryl (6-10C), alkylaryl (7-16C) or alkenylaryl (7-16C) each optionally further containing 1-4 heteroatoms (N, O or S) and wherein said optional substituents may include ═O; or

each of R 1 -R 5 is independently halo, NO 2 , SO, SO 2 , SO 2 NH 2 , —OH, SH or NH 2 , and wherein R 3 may be keto if n 3 =1; and

wherein two substituents on adjacent positions of the same ring may form a 3-7 membered saturated or unsaturated ring fused to said substituted ring, said fused ring itself optionally substituted and optionally containing one or more heteroatoms (N, S, O); or

wherein a combination of R 1 and R 2 and/or R 4 and R 5 may form a bond or a bridge between phenyl groups A and B and/or C and D; and

wherein each n 1 -n 2 and n 4 -n 5 is independently 0-4, and n 3 is 1-4; and/or

the compound of formula (1) is in the form of an isolated stereoisomer; or

the compound of formula (1) is P49 or P50 in FIG. ( 1 ) or a salt thereof.

2. The method of claim 1 wherein each of R 1 , R 2 , R 4 and R 5 is independently halo, or is optionally heteroatom containing and/or optionally substituted alkyl, alkenyl, aryl, alkylaryl, alkenylaryl, or phenoxy.

3. The method of claim 1 wherein R 1 and R 2 and/or R 4 and R 5 form a bridge of 1-3 members.

4. The method of claim 1 wherein n 3 is 1 and R 3 is COOH or an alkyl ester thereof.

5. The method of claim 1 wherein all of n 1 -n 2 and n 4 -n 5 are 0.

6. The method of claim 1 wherein one of n 1 -n 2 and n 4 -n 5 is 1 and the other n are 0.

7. The method of claim 1 wherein one of n 1 -n 2 and n 4 -n 5 is 2 and the other n are 0.

8. The method of claim 1 wherein one of n 1 -n 2 and n 4 -n 5 is 3 and the other n are 0.

9. The method of claim 1 which is compound P37-P50 in FIG. 1 or a salt thereof.

10. The method of claim 1 wherein the condition is pain.

11. The method of claim 1 wherein the condition is stroke.

12. The method of claim 1 wherein the condition is epilepsy.

13. The method of claim 1 wherein the condition is anxiety or depression.

14. The method of claim 5 wherein the condition is pain.

15. The method of claim 5 wherein the condition is stroke.

16. The method of claim 5 wherein the condition is epilepsy.

17. The method of claim 5 wherein the condition is anxiety or depression.

Assignments (3)
CHANGE OF NAME Recorded Sep 15, 2010
From: NEUROMED PHARMACEUTICALS LTD.
To: ZALICUS PHARMACEUTICALS LTD.
Reel/Frame 024990/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: SNUTCH, TERRANCE P.; ZAMPONI, GERALD W.; PAJOUHESH, HASSAN; PAJOUHESH, HOSSEIN; BELARDETTI, FRANCESCO
To: NEUROMED TECHNOLOGIES, INC.
Reel/Frame 024933/0306 →
CHANGE OF NAME Recorded Aug 11, 2006
From: NEUROMED TECHNOLOGIES INC.
To: NEUROMED PHARMACEUTICALS LTD.
Reel/Frame 018099/0664 →